NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more
NRx Pharmaceuticals operates at the intersection of psychiatric medicine and a national push to expand treatment options for treatment-resistant depression, post-traumatic stress disorder (PTSD), and suicidal ideation. Its core differentiator is a preservative-free formulation of ketamine, addressing a quality and safety gap in a market where standard formulations contain a preservative not listed as generally recognized as safe by the FDA. This product design supports a "branded generic" positioning that could command premium economics relative to commodity ketamine, especially amid intermittent U.S. supply shortages.
The company's market positioning rests on two distinct value streams. The first is the near-term, narrower-margin opportunity in preservative-free ketamine, where U.S.-based manufacturing and a differentiated formulation support an initial commercial ramp. The second is the branded NRX-100 opportunity for depression with suicidal ideation, a substantially larger addressable population that remains unproven and dependent on a future NDA approval. This structure means the company's medium-term trajectory depends less on one binary event and more on its ability to sequence a generic launch, scale manufacturing, and de-risk the branded regulatory pathway in parallel.
The most consequential near-term catalyst is the transition of preservative-free ketamine from regulatory approval to actual commercial launch. Management has indicated plans for a sizeable launch inventory and staged U.S. expansion through 2027, and execution on manufacturing validation, distribution channels, and clinical adoption will shape sentiment in the coming quarters. Quarterly earnings reports, with the next expected around late November 2026, will be watched for early revenue ramp and cash-consumption trends.
A second, larger catalyst is the regulatory trajectory of NRX-100. Following a Type C FDA meeting that analysts described as providing a clearer application pathway supported by real-world evidence, expectations have shifted toward potential FDA action. A favorable decision could materially expand the company's addressable market, while any delay would likely reset sentiment. Analysts at H.C. Wainwright raised their price target to $45 (from $40) citing this de-risking, while Ascendiant raised its target to $51 following the ketamine approval and Lucid Capital initiated coverage with a $49 target. In contrast, BTIG later lowered its target to $10, reflecting a more conservative view of the branded opportunity and funding risk.
Beyond the core programs, the DARPA (Defense Advanced Research Projects Agency) prime contract for robotic magnetic stimulation in treatment-resistant depression and the ALS-focused antibody program at subsidiary GeNeuro represent optionality that could add long-term value but are unlikely to drive near-term fundamentals.
The company's outlook is closely tied to the regulatory climate for psychiatric and psychedelic-adjacent therapies. A 2026 executive order aimed at accelerating medical treatments for serious mental illness signaled greater federal receptiveness to ketamine-based and related treatments, and NRx has applied for Commissioner's National Priority Vouchers that could shorten review timelines. Broader mental-health demand trends, including rising prevalence of depression and suicidality, underpin long-term market growth, with management and third-party estimates pointing to a ketamine market expanding from roughly $750 million toward several billion dollars over the coming decade.
As a pre-profitability biotech, NRx is also highly sensitive to financing conditions. Higher interest rates raise the cost of capital and can dampen appetite for speculative small-cap equities, while tighter credit conditions may increase dilution risk if the company must raise funds before reaching sustained revenue. Inflation in manufacturing and logistics inputs could pressure early launch margins, though U.S.-based production partially insulates the company from supply-chain volatility. These macro forces matter less to demand than to the company's ability to fund its transition to profitability.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool aims to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support more informed decision-making. For investors monitoring names like NRXP amid regulatory catalysts and launch execution, the Trend Prediction Engine can provide an additional, data-driven perspective on directional signals.
Looking into 2026 and beyond, NRx's outlook hinges on several structural themes. The first is commercial execution: converting an approved product into durable revenue requires building distribution, securing reimbursement, and displacing compounded ketamine in clinic settings, a time-intensive operational challenge. The second is regulatory progression of NRX-100 and NRX-101, the oral combination candidate for bipolar depression with suicidal ideation, where FDA action could redefine the company's addressable market and margin profile.
Longer term, cost structure and margin sustainability will depend on manufacturing scale and the ability to price a differentiated formulation above commodity levels. Capital allocation priorities—including the balance between funding commercialization and advancing the pipeline—will be closely scrutinized given the company's cash needs. Competitive threats include other ketamine formulations, alternative rapid-acting antidepressants, and emerging psychedelic therapies, all of which could compress the company's differentiation over time.
Consensus analyst expectations currently reflect an optimistic but divided view. Most covering firms maintain Buy or equivalent ratings, yet price targets range widely, signaling genuine uncertainty about the timing and probability of the branded NDA pathway. While some analysts see substantial upside tied to NRX-100, others emphasize dilution and execution risk. As such, the 2026 outlook should be framed around catalyst execution and capital sustainability rather than any single valuation assumption.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NUV | 8.29 | 0.07 | +0.89% |
| Nuveen Municipal Value Fund | |||
| MYY | 15.73 | 0.02 | +0.14% |
| ProShares Short S&P Mid Cap400 (MYY) | |||
| GFEB | 45.10 | -0.06 | -0.13% |
| FT Vest US Equity Moderate Buffer ETF February (GFEB) | |||
| CPNS | 28.24 | -0.04 | -0.15% |
| Calamos Nasdaq-100 Structured Alt Protection ETF - September (CPNS) | |||
| JHMU | 25.57 | -0.07 | -0.26% |
| John Hancock Dynamic Municipal Bond ETF (JHMU) | |||
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NRXP | 1D Price Change % | ||
|---|---|---|---|---|
| NRXP | 100% | -3.95% | ||
| TAOX - NRXP | 84% Closely correlated | -6.67% | ||
| ALLR - NRXP | 81% Closely correlated | +4.38% | ||
| PALI - NRXP | 74% Closely correlated | -1.75% | ||
| COYA - NRXP | 39% Loosely correlated | -4.28% | ||
| BCYC - NRXP | 36% Loosely correlated | -2.32% | ||
More | ||||
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
The RSI Oscillator for NRXP moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NRXP just turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 76 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.498). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.